Central composite design augmented quality-by-design-based systematic formulation of erlotinib hydrochloride-loaded chitosan-poly (lactic-co-glycolic acid) nanoparticles

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Nijhawan HP, Prabhakar B, Misra A, et al. Fragmented antibodies in non-small-cell lung cancer: a novel nano-engineered delivery system for detection and treatment of cancer. Drug Discov Today 2023;28(11):103701–103701. doi:10.1016/j.drudis.2023.103701
   PubMed Web of Science ®Google Scholar
• Chen C, Akerstrom V, Baus J, et al. Comparative analysis of the transduction efficiency of five adeno associated virus serotypes and VSV-G pseudotype lentiviral vector in lung cancer cells. Virol J. 201;10:86. doi:10.1186/1743-422X-10-86
   PubMed Web of Science ®Google Scholar
• Houston KA, Henley SJ, Li J, et al. Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009. Lung Cancer. 2014;86(1):22–28. doi:10.1016/j.lungcan.2014.08.001
   PubMed Web of Science ®Google Scholar
• Ohgino K, Soejima K, Yasuda H, et al. Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small-cell lung cancer. Lung Cancer. 2014;83(1):90–96. doi:10.1016/j.lungcan.2013.10.016
   PubMed Web of Science ®Google Scholar
• Zhao N, Zhang XC, Yan H, et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer. 2014;85(1):66–73. doi:10.1016/j.lungcan.2014.03.026
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou X, Gao Y, et al. Recent progress in development of new sonosensitizers for sonodynamic cancer therapy. Drug Discov Today 2014;19(4):502–509. doi:10.1016/j.drudis.2014.01.010
   PubMed Web of Science ®Google Scholar
• Cataldo VD, Gibbons DL, Pérez-Soler R, et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364(10):947–955. doi:10.1056/NEJMct0807960
   PubMed Web of Science ®Google Scholar
• Yang KM, Shin IC, Park JW, et al. Nanoparticulation improves bioavailability of Erlotinib. Drug Dev Ind Pharm. 2017;43(9):1557–1565. doi:10.1080/03639045.2017.1326931
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, et al. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77–85. doi:10.1200/JCO.2004.06.075
   PubMed Web of Science ®Google Scholar
• Marchetti S, De Vries NA, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008;7(8):2280–2287. doi:10.1158/1535-7163.MCT-07-2250
   PubMed Web of Science ®Google Scholar
• Bakhtiary Z, Barar J, Aghanejad A, et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small-cell lung cancer. Drug Dev Ind Pharm. 2017;43(8):1244–1253. doi:10.1080/03639045.2017.1310223
   PubMed Web of Science ®Google Scholar
• Mandal B, Mittal NK, Balabathula P, et al. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small-cell lung cancer. Eur J Pharm Sci. 2016;81:162–171. doi:10.1016/j.ejps.2015.10.021
   PubMed Web of Science ®Google Scholar
• Shiena K, Yamamoto H, Soh J, et al. Drug resistance to EGFR tyrosine kinase inhibitors for non-small-cell lung cancer. Acta Med Okayama. 2014;68(4):191–200. doi:10.18926/AMO/52785
   PubMed Web of Science ®Google Scholar
• Rodríguez F, Caruana P, De la Fuente N, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022;12(6):784. doi:10.3390/biom12060784
   PubMed Web of Science ®Google Scholar
• Etheridge ML, Campbell SA, Erdman AG, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1–14. doi:10.1016/j.nano.2012.05.013
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel. 2001;70(1–2):1–20. doi:10.1016/s0168-3659(00)00339-4
   PubMed Web of Science ®Google Scholar
• Hami Z. A brief review on advantages of nano-based drug delivery systems. Ann Mil Heal Sci Res. 2021;19(1):112274. doi:10.5812/amh.112274
   Google Scholar
• Raut H, Jadhav C, Shetty K, et al. Sorafenib tosylate novel drug delivery systems: implications of nanotechnology in both approved and unapproved indications. OpenNano. 2022;8:100103. doi:10.1016/j.onano.2022.100103
   Google Scholar
• Fulfager AD, Yadav KS. Understanding the implications of co-delivering therapeutic agents in a nanocarrier to combat multidrug resistance (MDR) in breast cancer. J Drug Deliv Sci Technol. 2021;62:102405. doi:10.1016/j.jddst.2021.102405
   Web of Science ®Google Scholar
• Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Rel. 2005;108(2–3):193–214. doi:10.1016/j.jconrel.2005.07.024
   PubMed Web of Science ®Google Scholar
• Zielinska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731. doi:10.3390/molecules25163731
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Rel. 2012;161(2):505–522. doi:10.1016/j.jconrel.2012.01.043
   PubMed Web of Science ®Google Scholar
• Joshi G, Sharma V, Saxena R, et al. Polylactic coglycolic acid (PLGA)-based green materials for drug delivery. In: Shakeel Ahmed, editor. Applications of Advanced Green Materials. Cambridge (UK): Woodhead Publishing; 2020. 425–440.
   Google Scholar
• Wu XS, Wang N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation. J Biomater Sci Polym Ed. 2001;12(1):21–34. doi:10.1163/156856201744425
   PubMed Web of Science ®Google Scholar
• D'Angelo I, Quaglia F, Ungaro F. PLGA carriers for inhalation: where do we stand, where are we headed? Ther Deliv. 2015;6(10):1139–1144. doi:10.4155/tde.15.37
   PubMedGoogle Scholar
• Elbatanony RS, Parvathaneni V, Kulkarni NS, et al. Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small-cell lung cancer (NSCLC)-development and in-vitro efficacy. Drug Deliv Transl Res. 2021;11(3):927–943. doi:10.1007/s13346-020-00802-8
   PubMed Web of Science ®Google Scholar
• Vaidya B, Parvathaneni V, Kulkarni NS, et al. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small-cell lung cancer. Int J Biol Macromol. 2019;122:338–347. doi:10.1007/s13346-020-00802-8
   PubMed Web of Science ®Google Scholar
• Vega E, Gamisans F, García ML, et al. PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J Pharm Sci. 2008;97(12):5306–5317. doi:10.1002/jps.21383
   PubMed Web of Science ®Google Scholar
• Wu J, Deng C, Meng F, et al. Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. J Control Rel. 2017;259:76–82. doi:10.1016/j.jconrel.2016.12.024
   PubMed Web of Science ®Google Scholar
• Allison SD. Analysis of initial burst in PLGA microparticles. Expert Opin Drug Deliv. 2008;5(6):615–628. doi:10.1517/17425247.5.6.615
   PubMed Web of Science ®Google Scholar
• Rodrigues de Azevedo C, von Stosch M, Costa MS, et al. Modeling of the burst release from PLGA micro- and nanoparticles as function of physicochemical parameters and formulation characteristics. Int J Pharm. 2017;532(1):229–240. doi:10.1016/j.ijpharm.2017.08.118
   PubMedGoogle Scholar
• Shen H, Hu X, Bei J, et al. The immobilization of basic fibroblast growth factor on plasma-treated poly(lactide-co-glycolide). Biomaterials. 2008;29(15):2388–2399. doi:10.1016/j.biomaterials.2008.02.008
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang J, Deng C, et al. Vitamin E-Oligo(methyl diglycol l-glutamate) as a biocompatible and functional surfactant for facile preparation of active tumor-targeting PLGA nanoparticles. Biomacromolecules. 2016;17(7):2367–2374. doi:10.1021/acs.biomac.6b00380
   PubMed Web of Science ®Google Scholar
• Lu B, Lv X, Le Y. Chitosan-modified PLGA nanoparticles for control-released drug delivery. Polymers (Basel). 2019;11(2):304. doi:10.3390/polym11020304
   PubMed Web of Science ®Google Scholar
• Wang Y, Li P, Kong L. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech. 2013;14(2):585–592. doi:10.1208/s12249-013-9943-3
   PubMed Web of Science ®Google Scholar
• Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed. 2006;1(2):117. doi:10.2147/nano.2006.1.2.117
   PubMed Web of Science ®Google Scholar
• Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm. 2010;399(1–2):1–11. doi:10.1016/j.ijpharm.2010.08.022
   PubMed Web of Science ®Google Scholar
• Gibot L, Chabaud S, Bouhout S, et al. Anticancer properties of chitosan on human melanoma are cell line dependent. Int J Biol Macromol. 2015;72:370–379. doi:10.1016/j.ijbiomac.2014.08.033
   PubMed Web of Science ®Google Scholar
• Mundargi RC, Babu VR, Rangaswamy V, et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control. Rel. 2008;125(3):193–209. doi:10.1016/j.jconrel.2007.09.013
   PubMed Web of Science ®Google Scholar
• Xu B, Jiang G, Yu W, et al. Preparation of poly(lactic-co-glycolic acid) and chitosan composite nanocarriers via electrostatic self assembly for oral delivery of insulin. Mater Sci Eng C Mater Biol Appl. 2017;78:420–428. doi:10.1016/j.msec.2017.04.113
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Rel. 2004;100(1):5–28. doi:10.1016/j.jconrel.2004.08.010
   PubMed Web of Science ®Google Scholar
• Radwan R, Abdelkader A, Fathi HA, et al. Development and evaluation of letrozole-loaded hyaluronic acid/chitosan-coated poly(d,l-lactide-co-glycolide) nanoparticles. J Pharm Innov. 2022;17(2):572–583. doi:10.1007/s12247-021-09538-5
   Web of Science ®Google Scholar
• Dangi RS, Shakya S. Preparation, optimization and characterization of PLGA nanoparticle. Int J Pharm Life Sci. 2013;4(7):2810–2818.
   Google Scholar
• Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic “design of experiments”. Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2005;22(1):27–105. doi:10.1615/critrevtherdrugcarriersyst.v22.i3.10
   PubMed Web of Science ®Google Scholar
• Vora C, Patadia R, Mittal K, et al. Risk based approach for design and optimization of stomach specific delivery of rifampicin. Int J Pharm. 2013;455(1–2):169–181. doi:10.1016/j.ijpharm.2013.07.043
   PubMedGoogle Scholar
• Soni G, Yadav KS, Gupta MK. Design of experiments (DoE) approach to optimize the sustained release microparticles of gefitinib. Curr Drug Deliv. 2019;16(4):364–374. doi:10.2174/1567201816666181227114109
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771. doi:10.1208/s12248-014-9598-3
   PubMed Web of Science ®Google Scholar
• Gasparini G, Kosvintsev SR, Stillwell MT, et al. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification. Colloids Surf B Biointerf. 2008;61(2):199–207. doi:10.1016/j.colsurfb.2007.08.011
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377. doi:10.3390/polym3031377
   PubMed Web of Science ®Google Scholar
• Verma P, Yadav KS. Quality by Design (QbD) enabled and Box-Behnken design assisted approach for formulation of tranexamic acid loaded stratum corneum lipid liposomes. J Drug Deliv Sci Technol. 2023;86:104571. doi:10.1016/j.jddst.2023.104571
   Web of Science ®Google Scholar
• Verma P, Yadav KS. Novel formulations for topical delivery of tranexamic acid: assessing the need of epidermal targeting for hyperpigmentation disorders. Expert Opin Drug Deliv. 2023;20(6):773–783. doi:10.1080/17425247.2023.2206645
   PubMed Web of Science ®Google Scholar
• Panigrahi D, Sahu PK, Swain S, et al. Quality by design prospects of pharmaceuticals application of double emulsion method for PLGA loaded nanoparticles. SN Appl Sci. 2021;3(6):1–21. doi:10.1007/s42452-021-04609-1
   Web of Science ®Google Scholar
• Fahmy R, Kona R, Dandu R, et al. Quality by design I: application of failure mode effect analysis (FMEA) and Plackett-Burman design of experiments in the identification of “main factors” in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride immediate-release tablets. AAPS PharmSciTech. 2012;13(4):1243–1254. doi:10.1208/s12249-012-9844-x
   PubMed Web of Science ®Google Scholar
• Beg S, Saini S, Bandopadhyay S, et al. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques. Drug Dev Ind Pharm. 2018;44(3):407–420. doi:10.1080/03639045.2017.1395459
   PubMed Web of Science ®Google Scholar
• Pal RR, Parashar P, Singh I, et al. Tamanu oil potentiated novel sericin emulgel of levocetirizine: repurposing for topical delivery against DNCB-induced atopic dermatitis, QbD based development and in vivo evaluation. J Microencapsul. 2019;36(5):432–446. doi:10.1080/02652048.2019.1637474
   PubMed Web of Science ®Google Scholar
• Gazori T, Khoshayand MR, Azizi E, et al. Evaluation of alginate/chitosan nanoparticles as antisense delivery vector: formulation, optimization and in vitro characterization. Carbohydr Polym. 2009;3(77):599–606. doi:10.1016/j.carbpol.2009.02.019
   Google Scholar
• Soni G, Yadav KS, Gupta MK. QbD based approach for formulation development of spray dried microparticles of erlotinib hydrochloride for sustained release. J Drug Deliv Sci Technol. 2020;57:01684. doi:10.1016/j.jddst.2020.101684
   Web of Science ®Google Scholar
• Bhargave H, Nijhawan H, Yadav KS. PEGylated erlotinib HCl injectable nanoformulation for improved bioavailability. AAPS PharmSciTech. 2023;24(4):101. doi:10.1208/s12249-023-02560-5
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Y, Hou S, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 2008;69(2):445–453. doi:10.1016/j.ejpb.2008.01.013
   PubMed Web of Science ®Google Scholar
• Yadav KS, Raut HC, Nijhawan HP. Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells. Pharm Dev Technol. 2023;28(8):755–767. doi:10.1080/10837450.2023.2251148
   PubMed Web of Science ®Google Scholar
• Esmaeili F, Atyabi F, Dinarvand R. Preparation of PLGA nanoparticles using TPGS in the spontaneous emulsification solvent diffusion method. J Exp Nanosci. 2007;2(3):183–192. doi:10.1080/17458080701393137
   Web of Science ®Google Scholar
• Yadav KS, Sawant KK. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech. 2010;11(3):1456. doi:10.1208/s12249-010-9519-4
   PubMed Web of Science ®Google Scholar
• Yadav K, Sawant K. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Deliv. 2010;7(1):51–64. doi:10.2174/156720110790396517
   PubMedGoogle Scholar
• Alimohammady M, Jahangiri M, Kiani F, et al. Highly efficient simultaneous adsorption of Cd(II), Hg(II) and As(III) ions from aqueous solutions by modification of graphene oxide with 3-aminopyrazole: central composite design optimization. New J Chem. 2017;41(17):8905–8919. doi:10.1039/C7NJ01450C
   Web of Science ®Google Scholar
• Soni G, Yadav KS. Fast-dissolving films of sumatriptan succinate: factorial design to optimize in vitro dispersion time. J Pharm Innov. 2015;10(2):166–174. doi:10.1007/s12247-015-9217-6
   Web of Science ®Google Scholar
• Ghafari S, Aziz HA, Isa MH, et al. Application of response surface methodology (RSM) to optimize coagulation-flocculation treatment of leachate using poly-aluminum chloride (PAC) and alum. J Hazard Mater. 2009;163(2–3):650–656. doi:10.1016/j.jhazmat.2008.07.090
   PubMed Web of Science ®Google Scholar
• Verma P, Singh RK, Wadhwa A, et al. Bimatoprost-loaded lipidic nanoformulation development using quality by design: liposomes versus solid lipid nanoparticles in intraocular pressure reduction. Nanomedicine (Lond). 2023;18(25):1815–1837. doi:10.2217/nnm-2023-0141
   Web of Science ®Google Scholar
• Sadeghi-Avalshahr A, Nokhasteh S, Molavi AM, et al. Synthesis and characterization of collagen/PLGA biodegradable skin scaffold fibers. Regen Biomater. 2017;4(5):309–314. doi:10.1093/rb/rbx026
   PubMed Web of Science ®Google Scholar
• Queiroz MF, Melo KRT, Sabry DA, et al. Does the use of chitosan contribute to oxalate kidney stone formation? Mar Drugs. 2014;13(1):141–158. doi:10.3390/md13010141
   PubMed Web of Science ®Google Scholar
• Ferrero F, Periolatto M. Antimicrobial finish of textiles by chitosan UV-curing. J Nanosci Nanotechnol. 2012;12(6):4803–4810. doi:10.1166/jnn.2012.4902
   PubMed Web of Science ®Google Scholar
• Chronopoulou L, Massimi M, Giardi MF, et al. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures. Colloids Surfaces B Biointerfaces. 2013;103:310–317. doi:10.1016/j.colsurfb.2012.10.063
   PubMed Web of Science ®Google Scholar
• Almoustafa HA, Alshawsh MA, Chik Z. Technical aspects of preparing PEG-PLGA nanoparticles as carrier for chemotherapeutic agents by nanoprecipitation method. Int J Pharm. 2017;533(1):275–284. doi:10.1016/j.ijpharm.2017.09.054
   PubMedGoogle Scholar
• Yadav KS, Jacob S, Sachdeva G, et al. Long circulating PEGylated PLGA nanoparticles of cytarabine for targeting leukemia. J Microencapsul. 2011;28(8):729–742. doi:10.3109/02652048.2011.615949
   PubMed Web of Science ®Google Scholar
• Yadav KS, Jacob S, Sachdeva G, et al. Intracellular delivery of etoposide loaded biodegradable nanoparticles: cytotoxicity and cellular uptake studies. J Nanosci Nanotechnol. 2011;11(8):6657–6667. doi:10.1166/jnn.2011.4225
   PubMed Web of Science ®Google Scholar
• Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Rel. 1987;5(1):37–42. doi:10.1016/0168-3659(87)90035-6
   Google Scholar
• Guideline, ICH Harmonised Tripartite. “Quality risk management”. Q9, Current step 4; 2005. p. 408.
   Google Scholar
• Lotllikar MV. QUALITY RISK MANAGEMENT (QRM): A REVIEW. J Drug Deliv Ther. 2013;3(2):149. doi:10.22270/jddt.v3i2.447
   Google Scholar
• Nair VN, Abraham B, MacKay J, et al. Taguchi's parameter design: a panel discussion. Technometrics. 1992;34(2):127. doi:10.1080/00401706.1992.10484904
   Web of Science ®Google Scholar
• Rao RS, Kumar CG, Prakasham RS, et al. The Taguchi methodology as a statistical tool for biotechnological applications: a critical appraisal. Biotechnol J. 2008;3(4):510–523. doi:10.1002/biot.200700201
   PubMedGoogle Scholar
• Asfaram A, Ghaedi M, Agarwal S, et al. Removal of basic dye Auramine-O by ZnS:Cu nanoparticles loaded on activated carbon: optimization of parameters using response surface methodology with central composite design. RSC Adv. 2015;5(24):18438–18450. doi:10.1039/C4RA15637D
   Web of Science ®Google Scholar
• Dülmer H. The factorial survey: design selection and its impact on reliability and internal validity. Sociol Methods Res. 2016;45(2):304–347. doi:10.1177/0049124115582269
   Web of Science ®Google Scholar
• Zendehboudi A, Li X. Desiccant-wheel optimization via response surface methodology and multi-objective genetic algorithm. Energy Convers Manag. 2018;174:649–660. doi:10.1016/j.enconman.2018.07.078
   Web of Science ®Google Scholar
• Kilickap E. Optimization of cutting parameters on delamination based on Taguchi method during drilling of GFRP composite. Expert Syst Appl. 2010;37(8):6116–6122. doi:10.1016/j.eswa.2010.02.023
   Web of Science ®Google Scholar
• Nwobasi VN, Igbokwe PK, Onu CE. Optimization of acid activated Ngbo clay catalysts in esterification reaction using response surface methodology. Asian J Phys Chem Sci. 2022;10(1):11–27. doi:10.9734/ajopacs/2022/v10i130147
   Google Scholar
• Gan Q, Wang T, Cochrane C, et al. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 2005;44(2–3):65–73. doi:10.1016/j.colsurfb.2005.06.001
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215–223. doi:10.1016/j.yexmp.2008.12.004
   PubMed Web of Science ®Google Scholar
• Cun D, Jensen DK, Maltesen MJ, et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur J Pharm Biopharm. 2011;77(1):26–35. doi:10.1016/j.ejpb.2010.11.008
   PubMed Web of Science ®Google Scholar
• Kim MK, Ki DH, Na YG, et al. Optimization of mesoporous silica nanoparticles through statistical design of experiment and the application for the anticancer drug. Pharm. 2021;13(2):184. doi:10.3390/pharmaceutics13020184
   Google Scholar
• Singh G, Pai RS. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin Drug Deliv. 2014;11(5):647–659. doi:10.1517/17425247.2014.890588
   PubMed Web of Science ®Google Scholar
• Jain GK, Pathan SA, Akhter S, et al. Mechanistic study of hydrolytic erosion and drug release behaviour of PLGA nanoparticles: influence of chitosan. Polym Degrad Stab. 2010;12(95):2360–2366. doi:10.1016/j.polymdegradstab.2010.08.015
   Google Scholar